Advertisement

Esophagus

, 8:151 | Cite as

Progress in multidisciplinary treatment for esophageal cancer in Japan as reflected in JCOG studies

  • Nobutoshi Ando
Congress Report: President's Lecture Lecture of the president for the 63rd Annual Meeting of the Japan Esophageal Society, 2009

Abstract

Changes in the standard treatment for esophageal cancer in Japan are reflected in the history of consecutive studies conducted by the Japan Esophageal Oncology Group (JEOG), a subgroup of the Japan Clinical Oncology Group (JCOG). Following the era of preoperative radiotherapy in the 1970s, the emphasis in surgical adjuvant therapy shifted from postoperative radiotherapy in the 1980s to postoperative chemotherapy including cisplatin as a key drug in the 1990s. Later, the optimal timing for perioperative adjuvant therapy returned to before surgery based on the results of a JCOG study (JCOG9907) that compared preoperative chemotherapy with postoperative chemotherapy in the late 2000s. Next, the clinical question of which is better, preoperative aggressive chemotherapy or preoperative chemoradiotherapy, still needs to be resolved. Concurrent chemoradiotherapy using cisplatin and 5-fluorouracil became a standard non-surgical treatment for esophageal cancer from the early 1990s onwards. Based on the preferable results of definitive chemoradiotherapy for unresectable advanced disease, definitive chemoradiotherapy was considered to be a possible alternative treatment modality in stage I esophageal cancer patients. Therefore, JEOG conducted a phase III study (JCOG0502) to demonstrate the non-inferiority of chemoradiotherapy compared with surgery in patients with stage I esophageal squamous cell carcinoma. If definitive chemoradiotherapy fails in patients with stage II/III esophageal cancer, salvage surgery is now recommended. Therefore, JEOG has initiated a phase II study (JCOG0909) to evaluate the efficacy and safety of this combined treatment modality.

Keywords

Esophageal squamous cell carcinoma Multidisciplinary treatment JCOG Surgical adjuvant therapy 

Notes

Acknowledgments

I would like to sincerely thank all of the members of the Japan Esophageal Oncology Group for patient accrual and Dr. Haruhiko Fukuda and members of the JCOG Data Center for data management and statistical support. I would also like to thank Mr. Jeremy Williams of the Oral Health Science Center of Tokyo Dental College for his review of this manuscript.

References

  1. 1.
    Shimoyama M, Fukuda H, Saijo N, et al. Japan Clinical Oncology Group (JCOG). Jpn J Clin Oncol. 1998;28:158–62.PubMedCrossRefGoogle Scholar
  2. 2.
    Fukuda H. Development of cancer cooperative groups in Japan. Jpn J Clinic Oncol. 2010;40:881–9.CrossRefGoogle Scholar
  3. 3.
    Akakura I, Nakamura Y, Kakegawa T, et al. Surgery of carcinoma of the esophagus with preoperative radiation. Chest. 1970;57:47–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Cooperative Clinical Study Group for Esophageal Carcinoma. Multidisciplinary treatment for esophageal carcinoma. Jpn J Clin Oncol. 1983;13:417–24.Google Scholar
  5. 5.
    Kasai M. Surgical treatment for carcinoma of the esophagus. J Jpn Surg Soc. 1980;81:845–53.Google Scholar
  6. 6.
    Iizuka T, Ide H, Kakegawa T, et al. Preoperative radioactive therapy for esophageal carcinoma. Randomized evaluation trial in eight institutions. Chest. 1988;93:1054–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Japanese Esophageal Oncology Group. A comparison of chemotherapy and radiotherapy as adjuvant treatment to surgery for esophageal carcinoma. Chest. 1993;104:203–7.CrossRefGoogle Scholar
  8. 8.
    Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232:225–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg. 1997;114:205–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and vindesine in advanced squamous cell carcinoma of the esophagus: Japan Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1991;21:176–9.PubMedGoogle Scholar
  11. 11.
    Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: Japan Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22:172–6.PubMedGoogle Scholar
  12. 12.
    Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG 9204. J Clin Oncol. 2003;24:4592–6.CrossRefGoogle Scholar
  13. 13.
    Kleinberg L, Forastiere A. Chemoradiation in the management of esophageal cancer. J Clin Oncol. 2007;25:4110–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Ando N, Kato H, Shinoda M, et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for localized squamous cell carcinoma of the thoracic esophagus (JCOG 9907). Proc 2008 Gastrointestinal Cancer Symposium, Orlando, USA.Google Scholar
  15. 15.
    Igaki H, Kato H, Ando N, et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). Proc Am Soc Clin Oncol. 2008;26:215s.Google Scholar
  16. 16.
    Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979–84.PubMedCrossRefGoogle Scholar
  17. 17.
    Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727–33.CrossRefGoogle Scholar
  18. 18.
    Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 2007;15:277–84.Google Scholar
  20. 20.
    Ishida K, Iizuka T, Ando N, et al. Phase II Study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: nine Japanese Institute Trial. Jpn J Clin Oncol. 1996;26:310–5.PubMedGoogle Scholar
  21. 21.
    Ishida K, Ando N, Yamamoto S, et al. Phase II Study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Shinoda M, Ando N, Kato H, et al. A multicenter randomized phase II (rPII)/III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303). Proc Am Soc Clin Oncol. 2010;28:314s.Google Scholar
  23. 23.
    Kato H, Sato A, Fukuda H, et al. A phase II trial of chemo-radiotherapy in patients with stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group study (JCOG 9708). Jpn J Clin Oncol. 2009;39:638–43.PubMedCrossRefGoogle Scholar
  24. 24.
    Igaki H, Kato H, Tachimori Y, et al. Clinicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinoma of the thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg. 2000;20:1089–94.CrossRefGoogle Scholar
  25. 25.
    Minashi K, Muro K, Kato K, et al. A phase II study of chemoradiotherapy in patients with stage II, III esophageal squamous cell carcinoma (ESSC): JCOG trial (JCOG9906). Proc 2008 Gastrointestinal Cancers Symposium.Google Scholar

Copyright information

© The Japan Esophageal Society and Springer 2011

Authors and Affiliations

  1. 1.Department of SurgeryTokyo Dental College Ichikawa General HospitalIchikawaJapan

Personalised recommendations